Skip to main content
SpringerLink
Log in

Hirntumoren

  • Chapter
PET/CT-Atlas

  • 3860 Accesses

Zusammenfassung

Bei den Gliomen (30 % aller intrakraniellen Tumoren) stehen CT und MRT an erster Stelle der Diagnostik, wobei der MRT aufgrund der besseren Weichteilauflösung und zusätzlicher funktioneller Modalitäten der Vorzug gegeben werden sollte. Mit diesen Verfahren sind aber Aussagen über Malignitätsgrad, Infiltration und Effekte auf umgebendes Gewebe, Differenzierung zwischen Rezidiv und Nekrose, Prognose und Therapieeffekte nur eingeschränkt möglich. Solche Aussagen können aus PET-Untersuchungen des Glukosestoffwechsels mit FDG, der Aminosäurenaufnahme und der Proteinsynthese mit 11C-Methionin, 18F-Fluorethyltyrosinund 18F-Fluordeoxyphenylalanin und der Proliferationsrate mit 18F-Deoxythymidin getroffen werden. Durch die zunehmende Verfügbarkeit von 18F-Tracern gewinnt die PET bei Gliomen an klinischer Bedeutung. Es sollte immer eine Koregistrierung zu Ergebnissen aus morphologischen bildgebenden Verfahren erfolgen, wofür auch schon Hybridgeräte (PET-MR) zum Einsatz kommen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, Reivich M (1988) Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62(6): 1074–1078

    Article  CAS  PubMed  Google Scholar 

  2. Arbizu J, Tejada S, Marti-Climent JM, Diez-Valle R, Prieto E, Quincoces G, Vigil C, Idoate MA, Zubieta JL, Penuelas I, Richter JA (2012) Quantitative volumetric analysis of gliomas with sequential MRI and (1)(1)C-methionine PET assessment: patterns of integration in therapy planning. Eur J Nucl Med Mol Imaging 39(5): 771–781

    Article  PubMed  Google Scholar 

  3. Barker FG, Chang SM, Valk PE, Pounds TR, Prados MD (1997) 18-fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79(1): 115–126

    Article  CAS  PubMed  Google Scholar 

  4. Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C, Henk C, Wunderbaldinger P, Czech T, Wadsak W, Kletter K (2003) Brain tumour imaging with PET: A comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 30(11): 1561–1567

    Article  CAS  PubMed  Google Scholar 

  5. Bisdas S, Ritz R, Bender B, Braun C, Pfannenberg C, Reimold M, Naegele T, Ernemann U (2013) Metabolic Mapping of Gliomas Using Hybrid MR-PET Imaging: Feasibility of the Method and Spatial Distribution of Metabolic Changes. Invest Radiol 48(5): 295–301

    Article  CAS  PubMed  Google Scholar 

  6. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, Pfannenberg C, Pichler BJ, Reimold M, Stegger L (2010) Hybrid PET/MRI of intracranial masses: Initial experiences and comparison to PET/CT. J Nucl Med 51(8): 1198–1205

    Article  PubMed  Google Scholar 

  7. Bustany P, Chatel M, Derlon JM, Darcel F, Sgouropoulos P, Soussaline F, Syrota A (1986) Brain tumor protein synthesis and histological grades: A study by positron emission tomography (PET) with C11-L–Methionine. J Neurooncol 3(4): 397–404

    Article  CAS  PubMed  Google Scholar 

  8. Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A, Baum RP (2011) Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: Assessment of individual probability of malignancy. Clin Nucl Med 36(10): 841–847

    Article  PubMed  Google Scholar 

  9. Catana C, Drzezga A, Heiss WD, Rosen BR (2012) PET/MRI for neurologic applications. J Nucl Med 53(12):1916–25

    Article  PubMed  Google Scholar 

  10. Chao ST, Suh JH, Raja S, Lee SY, Barnett G (2001) The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 96(3): 191–197

    Article  CAS  PubMed  Google Scholar 

  11. Chen W (2007) Clinical applications of PET in brain tumors. J Nucl Med 48(9): 1468–1481

    Article  PubMed  Google Scholar 

  12. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH (2005) Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG. J Nucl Med 46(6): 945–952

    CAS  PubMed  Google Scholar 

  13. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 25(30): 4714–4721

    Article  CAS  PubMed  Google Scholar 

  14. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T (2006) 18F-FDOPA PET imaging of brain tumors: Comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47(6): 904–911

    CAS  PubMed  Google Scholar 

  15. Crippa F, Alessi A, Serafini GL (2012) PET with radiolabeled aminoacid. Q J Nucl Med Mol Imaging 56(2): 151–162

    CAS  PubMed  Google Scholar 

  16. De Souza B, Brunetti A, Fulham MJ, Brooks RA, De Michele D, Cook P, Nieman L, Doppman JL, Oldfield EH, Di Chiro G (1990) Pituitary microadenomas: A PET study. Radiology 177(1): 39–44

    Article  PubMed  Google Scholar 

  17. De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, Salmon I, Brotchi J, Goldman S (2001) Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95(5): 746–750

    Article  PubMed  Google Scholar 

  18. Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, Kessler RM (1995) Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195: 47–52

    Article  CAS  PubMed  Google Scholar 

  19. Derlon JM, Petit-Taboue MC, Chapon F, Beaudouin V, Noel MH, Creveuil C, Courtheoux P, Houtteville JP (1997) The in vivo metabolic pattern of low-grade brain gliomas: A positron emission tomographic study using 18 F-fluorodeoxyglucose and 11 C-L-methylmethionine. Neurosurgery 40(2): 276–287

    Article  CAS  PubMed  Google Scholar 

  20. Di Chiro G (1987). Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 22(5): 360–371

    Article  CAS  PubMed  Google Scholar 

  21. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP (1982) Glucose utilization of cerebral gliomas measured by (18F) fluorodeoxyglucose and positron emission tomography. Neurology 32: 1323–1329

    Article  CAS  PubMed  Google Scholar 

  22. Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ (1987) Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: A PET study. Radiology 164: 521–526

    Article  CAS  PubMed  Google Scholar 

  23. Dunet V, Rossier C, Buck A, Stupp R, Prior JO (2012). Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: A systematic review and Metaanalysis. J Nucl Med 53(2): 207–214

    Article  CAS  PubMed  Google Scholar 

  24. Filss CP, Galldiks N, Stoffels G, Sabel M, Wittsack HJ, Turowski B, Antoch G, Zhang K, Fink GR, Coenen HH, Shah NJ, Herzog H, Langen KJ (2014) Comparison of 18F-FET PET and Perfusion- Weighted MR Imaging: A PET/MR Imaging Hybrid Study in Patients with Brain Tumors. J Nucl Med 55(4):540–5

    Article  CAS  PubMed  Google Scholar 

  25. Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, Jansen P, Coenen HH, Steiger HJ, Langen KJ (2007) Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48(4): 519–527

    Article  CAS  PubMed  Google Scholar 

  26. Floeth FW, Pauleit D, Wittsack HJ, Langen KJ, Reifenberger G, Hamacher K, Messing-Junger M, Zilles K, Weber F, Stummer W, Steiger HJ, Woebker G, Muller HW, Coenen H, Sabel M (2005) Multimodal metabolic imaging of cerebral gliomas: Positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg 102(2): 318–327

    Article  PubMed  Google Scholar 

  27. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W (2010) Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med 51(10): 1532–1538

    Article  PubMed  Google Scholar 

  28. Galldiks N, Kracht L, Burghaus L, Thomas A, Jacobs AH, Heiss WD, Herholz K (2006) Use of 11 C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 33: 516–524

    Article  CAS  PubMed  Google Scholar 

  29. Galldiks N, Kracht LW, Burghaus L, Ullrich RT, Backes H, Brunn A, Heiss WD, Jacobs AH (2010) Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging 9(1): 40–46

    CAS  PubMed  Google Scholar 

  30. Galldiks N, Langen KJ, Holy R, Pinkawa M, Stoffels G, Nolte KW, Kaiser HJ, Filss CP, Fink GR, Coenen HH, Eble MJ, Piroth MD (2012) Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med 53(7): 1048–1057

    Article  CAS  PubMed  Google Scholar 

  31. Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, Sabel M, Langen KJ (2013) Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F] Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 40(1): 22–33

    Article  CAS  PubMed  Google Scholar 

  32. Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, Erdem Z, Shah NJ, Fink GR, Coenen HH, Langen KJ (2013) Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med 54(12): 2046–2054

    Article  CAS  PubMed  Google Scholar 

  33. Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, Slart RH (2013) Value of 11 C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging 40(4): 615–635

    Article  CAS  PubMed  Google Scholar 

  34. Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM (2012) 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol 14(8): 1079–1089

    CAS  Google Scholar 

  35. Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, Tamiya T (2008) 11 C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35(11): 2009–2017

    Article  CAS  PubMed  Google Scholar 

  36. Heinzel A, Stock S, Langen KJ, Muller D (2012) Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur J Nucl Med Mol Imaging 39(7): 1089–1096

    Article  PubMed  Google Scholar 

  37. Heiss WD (2009) The potential of PET/MR for brain imaging. Eur J Nucl Med Mol Imaging 36: 105–112

    Article  Google Scholar 

  38. Heiss WD, Raab P, Lanfermann H (2011) Multimodality Assessment of Brain Tumors and Tumor Recurrence. J Nucl Med 52(10): 1585–1600

    Article  CAS  PubMed  Google Scholar 

  39. Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, Mendoza G, Weber-Luxenburger G, Lottgen J, Thiel A, Wienhard K, Heiss WD (1998) 11 C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50(5): 1316–1322

    Article  CAS  PubMed  Google Scholar 

  40. Herholz K, Langen KJ, Schiepers C, Mountz JM (2012). Brain Tumors. Seminars in Nuclear Medicine 42(6): 356–370

    Article  PubMed  PubMed Central  Google Scholar 

  41. Herholz K, Reulen HJ, von Stockhausen HM, Thiel A, Ilmberger J, Kessler J, Eisner W, Yousry TA, Heiss WD (1997) Preoperative activation and intraoperative stimulation of language-related areas in patients with glioma. Neurosurgery 41(6): 1253–1260

    Article  CAS  PubMed  Google Scholar 

  42. Holthoff VA, Herholz K, Berthold F, Widemann B, Schroder R, Neubauer I, Heiss WD (1993) In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 72(4): 1394–1403

    Article  CAS  PubMed  Google Scholar 

  43. Holzer T, Herholz K, Jeske J, Heiss WD (1993) FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 17(5): 681–687

    Article  CAS  PubMed  Google Scholar 

  44. Huang C, McConathy J (2013) Radiolabeled amino acids for oncologic imaging. J Nucl Med 54(7): 1007–1010

    Article  CAS  PubMed  Google Scholar 

  45. Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, McCoy M, Gobel G, la Fougere C, Virgolini IJ, Trinka E, Jacobs AH, Stockhammer G (2013) [18F]-fluoro-ethyl-L-tyrosine PET: A valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol 15(3): 341–351

    CAS  Google Scholar 

  46. Idema AJ, Hoffmann AL, Boogaarts HD, Troost EG, Wesseling P, Heerschap A, van der Graaf WT, Grotenhuis JA, Oyen WJ (2012) 3’-Deoxy-3’-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients. J Nucl Med 53(12): 1904–1910

    Article  CAS  PubMed  Google Scholar 

  47. Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, Wildrick DM, Sawaya R (2001) Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 3(3): 193–200

    CAS  Google Scholar 

  48. Jacobs AH, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L, Kaestle C, Wagner R, Wienhard K, Heiss WD (2001) Positronemission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358: 727–729

    Article  CAS  PubMed  Google Scholar 

  49. Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, Galldiks N, Klein JC, Sobesky J, Hilker R, Vollmar S, Herholz K, Wienhard K, Heiss WD (2005) 18F-fluoro-L-thymidine and 11Cmethylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 46(12): 1948–1958

    CAS  PubMed  Google Scholar 

  50. Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougere C (2012) MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 39(6): 1021–1029

    Article  CAS  PubMed  Google Scholar 

  51. Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, Niyazi M, Drexler M, Bartenstein P, Schnell O, Tonn JC, Thon N, Kreth FW, la Fougere C (2014) Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients. J Nucl Med 55(2): 198–203

    Article  CAS  PubMed  Google Scholar 

  52. Jarzabek MA, Sweeney KJ, Evans RL, Jacobs AH, Stupp R, O’Brien D, Berger MS, Prehn JH, Byrne AT (2013) Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): An integrated multidisciplinary commentary. Drug Discov Today 18(21–22): 1052–1066

    Article  PubMed  Google Scholar 

  53. Jeong SY, Lim SM (2012) Comparison of 3’-deoxy-3’-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Nucl Med Biol 39(7): 977–981

    Article  CAS  PubMed  Google Scholar 

  54. Kinoshita M, Arita H, Goto T, Okita Y, Isohashi K, Watabe T, Kagawa N, Fujimoto Y, Kishima H, Shimosegawa E, Hatazawa J, Hashimoto N, Yoshimine T (2012) A novel PET index, 18FFDG- 11 C-methionine uptake decoupling score, reflects glioma cell infiltration. J Nucl Med 53(11): 1701–1708

    Article  PubMed  Google Scholar 

  55. Kleihues P, Burger PC, Scheithauer B (1993) Histological typing of tumors of the central nervous system. Springer, Berlin

    Book  Google Scholar 

  56. Kracht L, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, Heiss WD (2003) Methyl-(11 C)-L-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30: 868–873

    Article  CAS  PubMed  Google Scholar 

  57. Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, Klein JC, Herholz K, Heiss WD (2004) Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: Local comparison with stereotactic histopathology. Clin Cancer Res 10(21): 7163–7170

    Article  CAS  PubMed  Google Scholar 

  58. Krings T, Schreckenberger M, Rohde V, Foltys H, Spetzger U, Sabri O, Reinges MH, Kemeny S, Meyer PT, Moller-Hartmann W, Korinth M, Gilsbach JM, Buell U, Thron A (2001) Metabolic and electrophysiological validation of functional MRI. J Neurol Neurosurg Psychiatry 71(6): 762–771

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. la Fougere C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC (2011) Molecular imaging of gliomas with PET: Opportunities and limitations. Neuro Oncol 13(8): 806–819

    Google Scholar 

  60. Langleben DD, Segall GM (2000) PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 41(11): 1861–1867

    CAS  PubMed  Google Scholar 

  61. Levivier M, Goldman S, Pirotte B, Brucher JM, Baleriaux D, Luxen A, Hildebrand J, Brotchi J (1995) Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F] fluorodeoxyglucose. J Neurosurg 82: 445–452

    Article  CAS  PubMed  Google Scholar 

  62. Luyten PR, Marien AJ, Heindel W, van Gerwen PH, Herholz K, den Hollander JA, Friedmann G, Heiss WD (1990) Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology 176(3): 791–799

    Article  CAS  PubMed  Google Scholar 

  63. Nariai T, Senda M, Ishii K, Maehara T, Wakabayashi S, Toyama H, Ishiwata K, Hirakawa K (1997) Three-dimensional imaging of cortical structure, function and glioma for tumor resection. J Nucl Med 38(10): 1563–1568

    CAS  PubMed  Google Scholar 

  64. Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N, Mineura K, Uemura K (1996) Clinical positron emission tomography for brain tumors: Comparison of fludeoxyglucose 18 F and L-methyl- 11 C-methionine. Am J Neuroradiol 17(2): 345–353

    CAS  PubMed  Google Scholar 

  65. Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, Shimosegawa E, Ito H, Hatazawa J, Okudera T, Uemura K, Yasui N (1993) Cerebral glioma: Evaluation with methionine PET. Radiology 186(1): 45–53

    Article  CAS  PubMed  Google Scholar 

  66. Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J, Kuyama J, Maruno H, Arimizu N (1991) The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J Nucl Med 32(4): 686–691

    CAS  PubMed  Google Scholar 

  67. Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, Kemp BJ, Grams MP, Morris JM, Hoover JM, Hu LS, Sarkaria JN, Brinkmann DH (2013) Biopsy validation of 18FDOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: Results of a prospective pilot study. Neuro Oncol 15(8): 1058–1067

    CAS  Google Scholar 

  68. Patronas NJ, Dichiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, Larson SM (1985) Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62: 816–822

    Article  CAS  PubMed  Google Scholar 

  69. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, Zilles K, Coenen HH, Langen KJ (2005) O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128(Pt 3): 678–687

    Article  PubMed  Google Scholar 

  70. Paulus W, Peiffer J (1989) Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 64(2): 442–447

    Article  CAS  PubMed  Google Scholar 

  71. Pietrzyk U, Herholz K, Heiss WD (1990) Three-dimensional alignment of functional and morphological tomograms. J Comput Assist Tomogr 14(1): 51–59

    Article  CAS  PubMed  Google Scholar 

  72. Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, Salmon I, Brotchi J, Levivier M (2004) Comparison of 18F-FDG and 11 C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 45(8): 1293–1298

    CAS  PubMed  Google Scholar 

  73. Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, Bruneau M, Rorive S, David P, Brotchi J (2009) Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: A survival analysis in 66 consecutive patients. Neurosurgery 64(3): 471–481; discussion 481

    Article  PubMed  Google Scholar 

  74. Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K (2004) Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31(11): 1464–1470

    Article  PubMed  CAS  Google Scholar 

  75. Popperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K (2007) FET PET for the evaluation of untreated gliomas: Correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34(12): 1933–1942

    Article  PubMed  Google Scholar 

  76. Rahm V, Boxheimer L, Bruehlmeier M, Berberat J, Nitzsche EU, Remonda L, Roelcke U (2014) Focal Changes in Diffusivity on Apparent Diffusion Coefficient MR Imaging and Amino Acid Uptake on PET Do Not Colocalize in Nonenhancing Low-Grade Gliomas. J Nucl Med 55(4):546–50

    Article  CAS  PubMed  Google Scholar 

  77. Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, Sabel M, Steiger HJ, Reifenberger G, Beez T, Coenen HH, Floeth FW, Langen KJ (2013) Diagnostic performance of 18F–FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med 54(2): 229–235

    Article  CAS  PubMed  Google Scholar 

  78. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H (1997) Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med 38(2): 280–287

    CAS  PubMed  Google Scholar 

  79. Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Langstrom B, Bolander H, Bergstrom M, Smits A (2001) Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer 92(6): 1541–1549

    Article  CAS  PubMed  Google Scholar 

  80. Ribom D, Smits A (2005) Baseline 11 C-methionine PET reflects the natural course of grade 2 oligodendrogliomas. Neurol Res 27(5): 516–521

    Article  PubMed  Google Scholar 

  81. Roelcke U, Radu EW, Hausmann O, Vontobel P, Maguire RP, Leenders KL (1998) Tracer transport and metabolism in a patient with juvenile pilocytic astrocytoma. A PET study. J Neurooncol 36(3): 279–283

    Article  CAS  PubMed  Google Scholar 

  82. Santra A, Kumar R, Sharma P, Bal C, Kumar A, Julka PD, Malhotra A (2012) F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur J Radiol 81(3): 508–513

    Article  PubMed  Google Scholar 

  83. Schlemmer HP, Pichler BJ, Krieg R, Heiss WD (2009) An integrated MR/PET system: Prospective applications. Abdom Imaging 34(6): 668–674

    Article  PubMed  Google Scholar 

  84. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, Wester HJ, Haubner R, Popperl G, Holtmannspotter M, Kretzschmar HA, Kessler H, Tonn JC, Schwaiger M, Beer AJ (2009) Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol 11(6): 861–870

    Google Scholar 

  85. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W (2012) 3’-deoxy-3’-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 53(1): 29–36

    Article  CAS  PubMed  Google Scholar 

  86. Shapiro WR (1992) Low-grade gliomas: When to treat? Ann Neurol 31(4): 437–438

    Article  CAS  PubMed  Google Scholar 

  87. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ (1998) Imaging proliferation in vivo with [18 F] FLT and positron emission tomography. Nature Medicine 4(11): 1334–1336

    Article  CAS  PubMed  Google Scholar 

  88. Shinomiya A, Kawai N, Okada M, Miyake K, Nakamura T, Kushida Y, Haba R, Kudomi N, Yamamoto Y, Tokuda M, Tamiya T (2013) Evaluation of 3’-deoxy-3’-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas. Eur J Nucl Med Mol Imaging 40(2): 175–185

    Article  CAS  PubMed  Google Scholar 

  89. Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC (2012) 11 C-methionine PET for grading and prognostication in gliomas: A comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med 53(11): 1709–1715

    Article  PubMed  Google Scholar 

  90. Singhal T, Narayanan TK, Jain V, Mukherjee J, Mantil J (2008). 11 C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 10(1): 1–18

    Article  PubMed  Google Scholar 

  91. Smits A, Baumert BG (2011) The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II. Int J Mol Imaging 2011: 372509

    Google Scholar 

  92. Spence AM, Muzi M, Mankoff DA, O’Sullivan SF, Link JM, Lewellen TK, Lewellen B, Pham P, Minoshima S, Swanson K, Krohn KA (2004) 18F-FDG PET of gliomas at delayed intervals: Improved distinction between tumor and normal gray matter. J Nucl Med 45(10): 1653–1659

    PubMed  Google Scholar 

  93. Steinmetz H, Huang YX, Seitz RJ, Knorr U, Schlaug G, Herzog H, Hacklander T, Freund HJ (1992) Individual integration of positron emission tomography and high-resolution magnetic resonance imaging. J Cereb Blood Flow Metab 12(6): 919–926

    Article  CAS  PubMed  Google Scholar 

  94. Tanaka Y, Nariai T, Momose T, Aoyagi M, Maehara T, Tomori T, Yoshino Y, Nagaoka T, Ishiwata K, Ishii K, Ohno K (2009) Glioma surgery using a multimodal navigation system with integrated metabolic images. J Neurosurg 110(1): 163–172

    Article  PubMed  Google Scholar 

  95. Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S (2005) Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 71(2): 161–168

    Article  CAS  PubMed  Google Scholar 

  96. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, Ohata K (2008) Diagnostic accuracy of 11 C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49(5): 694–699

    Article  PubMed  Google Scholar 

  97. Thiel A, Habedank B, Winhuisen L, Herholz K, Kessler J, Haupt WF, Heiss WD (2005) Essential language function of the right hemisphere in brain tumor patients. Ann Neurol 57(1): 128–131

    Article  PubMed  Google Scholar 

  98. Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomily RC, Hummel S, Scharnhorst J, Krohn KA, Spence AM (2002) Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 43(12): 1667–1673

    PubMed  Google Scholar 

  99. Tripathi M, Sharma R, D’Souza M, Jaimini A, Panwar P, Varshney R, Datta A, Kumar N, Garg G, Singh D, Grover RK, Mishra AK, Mondal A (2009) Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 34(12): 878–883

    Article  PubMed  Google Scholar 

  100. Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM, Bal J, Pandey S, Kumar N, Mishra AK, Mondal A (2012) Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med 37(2): 158–163

    Article  PubMed  Google Scholar 

  101. Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Nishikawa M, Ohata K, Torii K, Morino M, Nishio A, Hara M (2004) Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery—in malignant glioma. Ann Nucl Med 18(4): 291–296

    Article  CAS  PubMed  Google Scholar 

  102. Tyler JL, Diksic M, Villemure JG, Evans AC, Meyer E, Yamamoto YL, Feindel W (1987) Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 28: 1123–1133

    CAS  PubMed  Google Scholar 

  103. Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K, Neumaier B, Heiss WD, Wienhard K, Jacobs AH (2008) Glioma proliferation as assessed by 3’-fluoro-3’-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 14(7): 2049–2055

    Article  CAS  PubMed  Google Scholar 

  104. Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, Deckert M, Heiss WD, Jacobs AH (2009) Methyl-L-(11)C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma. Journal of Nuclear Medicine 50(12): 1962–1968

    Article  PubMed  Google Scholar 

  105. Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, Bormans G, Mortelmans L (2005) Direct comparison of 18F-FDG and 11 C-methionine PET in suspected recurrence of glioma: Sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 32(1): 39–51

    Article  CAS  PubMed  Google Scholar 

  106. Warburg O (1956) On the origin of cancer cells. Science 123: 309–314

    Article  CAS  PubMed  Google Scholar 

  107. Weber DC, Zilli T, Buchegger F, Casanova N, Haller G, Rouzaud M, Nouet P, Dipasquale G, Ratib O, Zaidi H, Vees H, Miralbell R (2008) [(18)F]Fluoroethyltyrosine- positron emission tomographyguided radiotherapy for high-grade glioma. Radiat Oncol 3: 44

    Article  PubMed  PubMed Central  Google Scholar 

  108. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, Molls M, Stocklin G, Schwaiger M (2000) O-(2-[18F]fluoroethyl)-Ltyrosine and L-[methyl-11C]methionine uptake in brain tumours: Initial results of a comparative study. Eur J Nucl Med 27(5): 542–549

    Article  CAS  PubMed  Google Scholar 

  109. Wunderlich G, Knorr U, Herzog H, Kiwit JC, Freund HJ, Seitz RJ (1998) Precentral glioma location determines the displacement of cortical hand representation. Neurosurgery 42(1): 18–26; discussion 26–17

    Article  CAS  PubMed  Google Scholar 

  110. Würker M, Herholz K, Voges J, Pietrzyk U, Treuer H, Bauer B, Sturm V, Heiss WD (1996) Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 23(5): 583–586

    Article  PubMed  Google Scholar 

  111. Wyss M, Hofer S, Bruehlmeier M, Hefti M, Uhlmann C, Bartschi E, Buettner UW, Roelcke U (2009) Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol 95(1): 87–93

    Article  CAS  PubMed  Google Scholar 

  112. Yamamoto T, Nishizawa S, Maruyama I, Yoshida M, Tsuchida T, Waki A, Fujibayashi Y, Kubota T, Yonekura Y, Itoh H (2001) Acute effects of stereotactic radiosurgery on the kinetics of glucose metabolism in metastatic brain tumors: FDG PET study. Ann Nucl Med 15(2): 103–109

    Article  CAS  PubMed  Google Scholar 

  113. Yamamoto Y, Ono Y, Aga F, Kawai N, Kudomi N, Nishiyama Y (2012)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Max-Planck-Institut für neurologische Forschung, Gleueler Straße 50, 50931, Köln

    Prof. Dr. med. Wolf-Dieter Heiss & Dr. med. Lutz Kracht

Authors
  1. Prof. Dr. med. Wolf-Dieter Heiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. Lutz Kracht
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Diagnostisch Therapeutisches Zentrum, Berlin, Deutschland

    Wolfgang Mohnike

  2. Königstein, Deutschland

    Gustav Hör

  3. Klinikum für Nuklearmedizin, Klinikum Fulda, Fulda, Deutschland

    Andreas Hertel

  4. UCLA Molecular & Medical Pharmacology, Los Angeles, CA, USA

    Heinrich Schelbert

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Heiss, WD., Kracht, L. (2016). Hirntumoren. In: Mohnike, W., Hör, G., Hertel, A., Schelbert, H. (eds) PET/CT-Atlas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48842-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48842-3_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48841-6

  • Online ISBN: 978-3-662-48842-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation